Towa Pharmaceutical Co., Ltd. Stock price

Equities

4553

JP3623150004

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-03-28 am EDT 5-day change 1st Jan Change
2,930 JPY -1.21% Intraday chart for Towa Pharmaceutical Co., Ltd. +0.58% +24.57%
Sales 2024 * 230B 1.52B Sales 2025 * 246B 1.62B Capitalization 144B 952M
Net income 2024 * 12.72B 83.97M Net income 2025 * 11.66B 76.99M EV / Sales 2024 * 1.33 x
Net Debt 2024 * 163B 1.07B Net Debt 2025 * 162B 1.07B EV / Sales 2025 * 1.24 x
P/E ratio 2024 *
11.3 x
P/E ratio 2025 *
12.4 x
Employees 4,298
Yield 2024 *
2.05%
Yield 2025 *
2.06%
Free-Float 47.46%
More Fundamentals * Assessed data
Dynamic Chart
Towa Pharmaceutical Completes Payment for Director Stock Compensation MT
VIE STYLE, Inc. announced that it has received ¥305 million in funding from Otsuka Holdings Co., Ltd., KAYAC Inc., Taisho Pharmaceutical Holdings Co., Ltd., Towa Pharmaceutical Co., Ltd., PE&HR Co., Ltd., Murata Manufacturing Co., Ltd. and other investors CI
Towa Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Towa Pharmaceutical Co., Ltd. completed the acquisition of Sunsho Pharmaceutical Co., Ltd. from Carlyle Japan Partners III, a fund managed by The Carlyle Group Inc. (NasdaqGS:CG). CI
Towa Pharmaceutical Co., Ltd. agreed to acquire Sunsho Pharmaceutical Co., Ltd. from Carlyle Japan Partners III, a fund managed by The Carlyle Group Inc. (NasdaqGS:CG) for ¥47.7 billion. CI
Protosera, Inc. announced that it expects to receive funding from Towa Pharmaceutical Co., Ltd. CI
Luye Pharma : Strikes Licensing Deal with Japan's Towa Pharma for Alzheimer's Disease Drug MT
Luye Pharma Switzerland AG and Towa Pharmaceutical Co., Ltd. Enters Strategic Collaboration to Develop and Commercialize Rivastigmine Multi-Day Transdermal Patch in Japan CI
Towa Pharmaceutical Co., Ltd. completed the acquisition of Pensa Investments S.L. from Esteve Pharmaceuticals, S.A. CI
Innophys Co., Ltd. announced that it has received ¥3.53 billion in funding from a group of investors CI
Towa Pharmaceutical Co., Ltd. signed an agreement to acquire Pensa Investments S.L. from Esteve Pharmaceuticals, S.A. CI
Innophys Co., Ltd. announced that it expects to receive funding from Hi-Lex Corporation CI
Towa Pharmaceutical Co., Ltd. Announces Earnings Results for the Second Quarter of Fiscal Year 2016; Provides Earnings Guidance for the Full Year Ending March 2016; Revises Capital Expenditure Guidance for the Year Endings March 2017 and 2018 CI
Towa Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter Ended December 2015; Reaffirms Earnings Guidance for the Full Year Ending March 2016 CI
Certain common shares of Towa Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 19-JAN-2016. CI
More news
1 day-1.21%
1 week+0.58%
Current month+5.06%
1 month+3.17%
3 months+24.31%
6 months+1.07%
Current year+24.57%
More quotes
1 week
2 899.00
Extreme 2899
3 015.00
1 month
2 691.00
Extreme 2691
3 015.00
Current year
2 326.00
Extreme 2326
3 240.00
1 year
1 703.00
Extreme 1703
3 240.00
3 years
1 703.00
Extreme 1703
3 560.00
5 years
1 703.00
Extreme 1703
3 560.00
10 years
1 193.33
Extreme 1193.3333
3 560.00
More quotes
Managers TitleAgeSince
President 72 79-04-30
Chief Administrative Officer - -
Director/Board Member - -
Members of the board TitleAgeSince
President 72 79-04-30
Corporate Officer/Principal 70 81-08-31
Director/Board Member 75 15-05-31
More insiders
Date Price Change Volume
24-03-28 2,930 -1.21% 123 200
24-03-27 2,996 +1.08% 164,700
24-03-26 2,964 +1.86% 165,600
24-03-25 2,910 -1.15% 160,000
24-03-22 2,944 -1.14% 166,200

Delayed Quote Japan Exchange, March 28, 2024 at 02:00 am EDT

More quotes
Towa Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The main products are generic drugs, which are launched after the efficacy and safety of new drugs have been confirmed for a certain period of time. It is a drug with the same effect, usage and dosage. The Company is involved in the sale and outsourced manufacture of products and generic drugs. The Company is involved in the research and outsourced manufacture of active pharmaceutical ingredient and soft capsules. The Company is also involved in the planning, development, contract manufacturing of health foods, general foods, miscellaneous goods and others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2,930 JPY
Average target price
3,690 JPY
Spread / Average Target
+25.94%
Consensus
  1. Stock
  2. Equities
  3. Stock Towa Pharmaceutical Co., Ltd. - Japan Exchange